Jazz Pharmaceuticals PLC (JAZZ) intrinsic value & 10-year financials
Jazz Pharmaceuticals PLC (JAZZ) has a Graham intrinsic value of $248.81 per share. At $210.23 on Oct 17, 2026, the stock trades 16% below that value. Over the last 10 fiscal years revenue grew 12.4% a year to $4.3B, with an average return on invested capital of 7.5%.
- Graham intrinsic value
- $248.81
- Share price (Oct 17, 2026)
- $210.23
- Price vs Graham value
- 16% below
- Market cap
- $12.8B
- Revenue (FY2025)
- $4.3B
- Revenue growth (10-yr CAGR)
- 12.4%
- ROIC (10-yr avg)
- 7.5%
- Free cash flow (FY2025)
- $1.3B
JAZZ 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $4.3B | -$356.1M | -$5.84 | $1.3B | -10.1% | -3.0% |
| FY2024 | $4.1B | $560.1M | $8.65 | $1.4B | 17.6% | 9.0% |
| FY2023 | $3.8B | $414.8M | $6.10 | $1.1B | 15.1% | 7.2% |
| FY2022 | $3.7B | -$224.1M | -$3.58 | $1.2B | -1.8% | -0.4% |
| FY2021 | $3.1B | -$329.7M | -$5.52 | $750.9M | 5.5% | 2.4% |
| FY2020 | $2.4B | $238.6M | $4.22 | $884.6M | 16.0% | 7.3% |
| FY2019 | $2.2B | $523.4M | $9.09 | $736.3M | 24.6% | 12.9% |
| FY2018 | $1.9B | $447.1M | $7.30 | $778.5M | 32.5% | 13.1% |
| FY2017 | $1.6B | $487.8M | $7.96 | $664.1M | 32.7% | 14.2% |
| FY2016 | $1.5B | $396.8M | $6.41 | $582.7M | 39.8% | 12.5% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Jazz Pharmaceuticals plc is a consistent compounder, expanding top-line revenue at 12.4% annually over the past decade.
Jazz Pharmaceuticals plc has historically struggled to out-earn its cost of capital, averaging just 7.5% ROIC.
Over the decade, Jazz Pharmaceuticals plc shows that the company has leveraged its balance sheet to sustain operations.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Jazz Pharmaceuticals plc is modeled at 12.4% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $248.81 per share.